Barinthus Biotherapeutics plc
BRNS
$1.20
$0.0151.27%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -100.20% | -25.90% | -88.71% | 152.82% | -50.83% |
Gross Profit | 100.20% | 25.90% | 88.71% | 1,853.75% | 27.13% |
SG&A Expenses | 113.64% | 103.23% | -124.73% | 1,045.06% | -45.15% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | 97.75% | -480.00% | -- | -- | -- |
Total Operating Expenses | 24.95% | 24.69% | -86.30% | 59.26% | -32.62% |
Operating Income | -24.95% | -24.69% | 86.30% | 39.58% | 31.75% |
Income Before Tax | -24.78% | -26.50% | -13.68% | 44.73% | 32.09% |
Income Tax Expenses | -257.14% | 40.54% | 100.37% | 99.50% | 99.38% |
Earnings from Continuing Operations | -24.69% | -26.66% | -19.09% | 42.39% | 28.88% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -83.33% | -67.74% | 1,800.00% | -60.53% | -45.45% |
Net Income | -24.77% | -26.85% | -18.78% | 42.34% | 28.87% |
EBIT | -24.95% | -24.69% | 86.30% | 39.58% | 31.75% |
EBITDA | -22.78% | -21.86% | 89.17% | 41.43% | 33.04% |
EPS Basic | -20.73% | -22.15% | -14.12% | 43.65% | 30.01% |
Normalized Basic EPS | -20.89% | -22.39% | 90.09% | 44.33% | 33.19% |
EPS Diluted | -20.73% | -22.50% | -13.62% | 43.24% | 30.05% |
Normalized Diluted EPS | -20.89% | -22.39% | 90.09% | 44.33% | 33.19% |
Average Basic Shares Outstanding | 3.34% | 3.85% | 4.07% | 2.30% | 1.65% |
Average Diluted Shares Outstanding | 3.34% | 3.85% | 4.07% | 2.30% | 1.65% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |